Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by PTGIR is a member of the G-protein coupled receptor family 1 and has been shown to be a receptor for prostacyclin. Additionally we are shipping Prostacyclin Receptor Proteins (5) and Prostacyclin Receptor Kits (4) and many more products for this protein.
Showing 10 out of 66 products:
Human Polyclonal Prostacyclin Receptor Primary Antibody for WB - ABIN2801905
Boie, Rushmore, Darmon-Goodwin, Grygorczyk, Slipetz, Metters, Abramovitz: Cloning and expression of a cDNA for the human prostanoid IP receptor. in The Journal of biological chemistry 1994
Show all 4 references for ABIN2801905
Human Polyclonal Prostacyclin Receptor Primary Antibody for IF, ELISA - ABIN1535983
Nakagawa, Tanaka, Usui, Harada, Sasaki, Itoh, Yoshimasa, Namba, Narumiya, Nakao: Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. in Circulation 1994
Human Polyclonal Prostacyclin Receptor Primary Antibody for IHC (p) - ABIN4348406
Li, Hoxha, Lama, Dinh, Vo, Dauwalder: The hector G-protein coupled receptor is required in a subset of fruitless neurons for male courtship behavior. in PLoS ONE 2011
Deletion of the I prostanoid receptor had no effect on the attenuation of atherogenesis by mPGES-1 (show PTGES Antibodies) deletion in the low-density lipoprotein receptor (show LDLR Antibodies) knockout mice.
Prostacyclin promotes the up-regulation of Nox4 (show NOX4 Antibodies) in endothelial cells, which opens up a novel strategy that protects and enhances endothelial cell functions in cardiovascular disease, such as repair after myocardial infarction or other ischemic conditions.
Its signaling increase cAMP concentration, which prototes sysnesis of HGF (show HGF Antibodies), causing angiogenesis.
an essential role of the COX-2 (show COX2 Antibodies)/PGI2 receptor axis in the cardioprotection afforded by the late ischemic preconditioning
findings suggest the IP receptor might maintain an angiogenic switch in the "on" state in tumor endothelial cells (TEC); suggest that the IP receptor is a TEC-specific marker and might be a useful therapeutic target
PGI2-induced PPAR delta (show PPARD Antibodies) activation accelerates blastocyst hatching in mice
For the first time these results show that activation of prostaglandin I2 receptor can attenuate damage following cerebral ischemia.
identify PGI(2)-prostaglandin I2 receptor as an important pathway for inhibiting allergic pulmonary inflammation by controlling recruitment of CD4 (show CD4 Antibodies)(+) Th2 cells into the inflammatory site
The prostacyclin/IP pathway suppresses cardiac fibrosis, at least partly, by inducing CREB (show CREB1 Antibodies) phosphorylation.
Prostaglandin I2 receptor signaling promotes T helper cell type (Th)1 (show TH1L Antibodies) differentiation through a cyclic adenosine monophosphate (AMP (show TMPRSS5 Antibodies))-protein kinase A pathway, thereby initiating acquired cutaneous immune responses.
these findings suggest that reduced IPR expression in DM2 (show CNBP Antibodies) platelets may contribute to platelet hyperactivity in humans with type 2 diabetes.
Prostaglandin I2- Prostaglandin I2 receptor signaling regulates human Th17 and Treg cell differentiation.
these data provide critical insights into the transcriptional regulation of the human prostacyclin receptor gene within the vasculature, including during megakaryocytic differentiation
IP receptor heteridimerization with thromboxane receptor (show TBXA2R Antibodies) facilitates receptor trafficking to membrane lipid rafts.
Prostacyclin receptor-dependent inhibition of human erythroleukemia cell differentiation is STAT3 (show STAT3 Antibodies)-dependent
IKEPP (show PDZD3 Antibodies) was also found to be expressed in vascular endothelial cells where it co-localizes and complexes with the hIP
the IP receptor was expressed in blood vessels of renal cell carcinoma specimens, but not in glomerular vessels of normal renal tissue; findings suggest the IP receptor might maintain an angiogenic switch in the "on" state in tumor endothelial cells (TEC); suggest that the IP receptor is a TEC-specific marker and might be a useful therapeutic target
VDAC is the ATP conduit in the IP receptor-mediated signaling pathway in human erythrocytes.
Human prostacyclin receptor interacts with the PDZ (show INADL Antibodies) adapter protein (show TOLLIP Antibodies) PDZK1 (show PDZK1 Antibodies); this interaction plays important role in endothelial cell migration and angiogenesis.
IP(R212C) exerts a dominant action on the wild-type IP and thromboxane receptor (show TBXA2R Antibodies) through dimerization. This likely contributes to accelerated cardiovascular disease in individuals carrying 1 copy of the variant allele.
The protein encoded by this gene is a member of the G-protein coupled receptor family 1 and has been shown to be a receptor for prostacyclin. Prostacyclin, the major product of cyclooxygenase in macrovascular endothelium, elicits a potent vasodilation and inhibition of platelet aggregation through binding to this receptor.
, PGI2 receptor
, prostacyclin receptor
, prostaglandin I2 receptor
, prostanoid IP receptor
, prostaglandin I receptor (IP)